Investigators who developed an experimental murine model of autoimmune encephalomyelitis found a significant correlation between visual function and structure and overall motor-sensory impairment.

Read More: ow.ly/KCCc50Ry4TX

At ARVO, Qinqin Zhang, PhD, presented a poster titled 'A unified deep learning model for geographic atrophy segmentation: Adaptable to SS-OCT and SD-OCT data with multiple scan patterns.' At the conference she gave Ophthalmology Times an overview.

Watch: ow.ly/uHqP50Ry4QP

Happening now! Join the live stream of Novel Therapies for Neovascular Retinal Disease! Join here: gotoper.com/ang2-bc

Adherence and tolerability are key in treatment of hypertension and glaucom. Priorities can ensure optimal outcomes for patients diagnosed with diseases.

Read More: ow.ly/WCE550Ry4Qm

Cynthia Roberts, PhD, sat down to discuss a 5-year prospective study to compare ocular stiffness parameters in, diabetes with retinopathy, diabetes without retinopathy, and normal subjects at this year's ARVO

Watch: ow.ly/zfVZ50Ry4PR

Study reveals lower vision specific quality of life in children with cortical/cerebral visual impairment. Investigators recruited children with CVI and normal controls who were between the ages of 12 months and 12 years.

Read More: ow.ly/2G4R50Ry4OG

Four studies presented at ARVO's 2024 Annual Meeting unveiled findings with the potential to revolutionize the retina field. Read about retinitis pigmentosa, macular pigment optical density, inherited retinal diseases and more: ophthalmologytimes.com/view/arvo-2024…

A recent chart review presented at this year's ARVO meeting showed that diabetic retinopathy is associated with older age, longer duration of type 1 diabetes, earlier onset of type 1 diabetes, and some modifiable risk factors. Read more: ophthalmologytimes.com/view/study-ide…

A chart review showed that diabetic retinopathy (DR) is associated with older age, longer duration of type 1 diabetes, earlier onset of type 1 diabetes, and some modifiable risk factors.

Read More: ow.ly/aCFN50Rxrni

At this year's ARVO meeting, Paolo Silva, MD, presented data on Protocol AA on behalf of the DRCR Retina Network and the effect of diabetic retinopathy lesion location and severity on the risk for progression in the long term.

Watch: ow.ly/B1JU50RxrgW

Stay up-to-date with the latest insights every Monday courtesy of Freddie! Delve into the crucial aspects of treatment for hypertension and glaucoma: adherence and tolerability.
Read now! ow.ly/XUuN50RxfIc

Aurion Biotech announced dosing of all subjects in its Phase 1/2 CLARA trial of AURN001, a combination cell therapy product comprised of neltependocel and Y-27632 for the treatment of corneal edema secondary to corneal endothelial dysfunction

Read More: ow.ly/1wj450RsV2l

Inflammasome Therapeutics has dosed the first patient in its Phase 1 clinical trial evaluating Kamuvudine-8 in subjects with geographic atrophy (GA). K8 is administered to the back of the eye via a sustained released intravitreal implant.

Read More: ow.ly/kNiY50RsUUO

With less than a day until one of ophthalmology’s biggest conferences of the year, companies and organizations are eagerly sharing information about the data and pipeline updates they plan to provide at the ARVO 2024 meeting.

Read More: ow.ly/ls9E50RsVv3

Adaptilens has announced the closing of a Series A financing round of $17.5 million to help drive the development of the company's Accommodating Intraocular Lens (A-IOL).

Read More: ow.ly/BnUq50RsUWS

Aurion Biotech announced dosing of all subjects in its Phase 1/2 CLARA trial of AURN001, a combination cell therapy product comprised of neltependocel and Y-27632 for the treatment of corneal edema secondary to corneal endothelial dysfunction

Read More: ow.ly/1wj450RsV2l

Coave Therapeutics announced that preclinical studies on its novel Conjugated AAV (coAAV) gene therapy vectors demonstrate promising results for ocular gene therapy.

Read More: ow.ly/ZA2950Rsqce

David Hutton, Managing Editor of Ophthalmology Times sat down with Claris Bio CEO, Clarke Atwell, to discuss the company's path toward developing treatment for neurotrophic keratitis.

Listen: ow.ly/TXPc50Rsq6e

Inflammasome Therapeutics has dosed the first patient in its Phase 1 clinical trial evaluating Kamuvudine-8 in subjects with geographic atrophy (GA). K8 is administered to the back of the eye via a sustained released intravitreal implant.

Read More: ow.ly/kNiY50RsUUO

Adaptilens has announced the closing of a Series A financing round of $17.5 million to help drive the development of the company's Accommodating Intraocular Lens (A-IOL).

Read More: ow.ly/BnUq50RsUWS